Therapeutic Hypothermia in
Perinatal Asphyxia
Rabindran1, Gedam
DS2
1Dr. Rabindran, Consultant Neonatologist, Billroth Hospital, Chennai,
India, 2Dr D Sharad Gedam, Professor of Pediatrics, L N Medical college,
Bhopal, MP, India
Address for
Correspondence: Dr Rabindran, E mail:
rabindranindia@yahoo.co.in
Abstract
Therapeutic hypothermia for infants with perinatal asphyxia has been
studied in several randomised controlled trials. There is convincing
evidence that moderate therapeutic hypothermia (33-34°C for 72
h), when initiated within 6 h after birth among term &
near-term infants (≥35 weeks) with moderate to severe HIE
reduces the risk of death or major disability & increases the
rate of disability-free survival at 6-7 years of age
Key words: Therapeutic
hypothermia, Asphyxia, perinatal asphyxia
Manuscript received:
19th Jan 2016, Reviewed:
01s t Feb 2016
Author Corrected;
10th Feb 2016, Accepted
for Publication: 20th Feb 2016
Introduction
Asphyxia is a major problem worldwide as 10% to 60% of affected infants
die, & at least 25% of survivors have long-term
neurodevelopmental sequelae. Therapeutic hypothermia for infants with
perinatal asphyxia has been studied in several randomised controlled
trials. There is convincing evidence that moderate therapeutic
hypothermia (33-34°C for 72 h), when initiated within 6 h after
birth among term & near-term infants (≥35 weeks) with
moderate to severe HIE reduces the risk of death or major disability
& increases the rate of disability-free survival at 6-7 years
of age. Hypothermia results in a graded reduction in cerebral
metabolism, suppresses apoptotic processes & also suppresses
the release of pro-inflammatory cytokines & interleukins.The
target body temperature is 34.5 ◦C for selective head cooling &
33.5 ◦C for total body cooling. Active cooling should be done for 72
hours & then gradual rewarming is done over 12 hours. Whole
body cooling provides homogeneous cooling whereas selective head
cooling provides greater cooling to the periphery of the brain than to
the deeper brain structures. Though there were no reported serious
adverse effects in the initial pilot studies of hypothermia in
newborns, potential side effects reported later include bradycardia,
arrhythmias, Hypotension, Reduction in surfactant production, Altered
coagulation cascade, Thrombocytopaenia, Leukopaenia, lactic acidosis,
Hypokalaemia & Hypoglycaemia. With the development of newer
modes of servo controlled hypothermia devices the cerebral insult due
to asphyxia can be reduced & severe sequlae of HIE can be
prevented.
Asphyxia-Problem Statement: Perinatal asphyxia affects 3-5 newborns per
1000 live births with subsequent moderate or severe hypoxic ischaemic
encephalopathy (HIE) in 0.5 to 1 per 1000 live births [1,2]. HIE is a
major problem worldwide as 10% to 60% of affected infants die, and at
least 25% of survivors have long-term neurodevelopmental sequelae
[3,4]. Globally, perinatal asphyxia is responsible for 42 million
disability life adjusted years, double that due to diabetes &
three quarters of that due to HIV/AIDS [5]. Almost one quarter of the
world’s 4 million annual neonatal deaths are caused by
perinatal asphyxia [6]. These account for as many deaths as does
malaria.
Therapeutic Hypothermia-Evidence: Therapeutic hypothermia for infants
with perinatal asphyxia has been studied in several randomised
controlled trials (RCT) [7-10]. Meta-analyses show that
therapeutic hypothermia increases survival with normal neurological
function (pooled risk ratio of 1.53) with a number needed to treat
(NNT) of 8 & in survivors reduces the rates of severedisability
& cerebral palsy [11,12]. A systematic review of three trials
showed a significant reduction of combined rate of death &
severe disability with NNT of 9 & increased normal survival
(survival without cerebral palsy & with MDI & PDI
>84 & normal vision & hearing) with a NNT of 8
[12]. In a Cochrane review of 11 RCT comprising 1505 infants with
moderate/severe encephalopathy &evidence of intrapartum
asphyxia, therapeutic hypothermia resulted in a statistically
significant reduction in combined outcome of mortality or major
neurodevelopmental disability to 18 months of age (RR 0.75,RD -0.15);
NNT for an additional beneficial outcome being 7. Cooling
resulted in statistically significant reductions in mortality (RR 0.75,
RD -0.09); NNT 11 & significant reductions in
neurodevelopmental disability among survivors (RR 0.77, RD -0.13); NNT
8 [13]. A 2013 Cochrane review found that therapeutic hypothermia is
useful in full term babies with encephalopathy [13]. There is
convincing evidence that moderate therapeutic hypothermia
(33-34°C for 72 h), when initiated within 6 h after birth among
term & near-term infants (≥35 weeks) with moderate to
severe HIE reduces the risk of death or major disability [12,13,14]
& increases the rate of disability-free survival at 6-7 years
of age [10,15].
Hypothermia Trials: Cool Cap trial used selective head cooling with
mild systemic hypothermia (rectal temperature 34-35°C)
commenced within 5.5 hours of age for 72 hours & showed an
independent protective effect of hypothermia on the primary outcome of
death or disability at 18 months (odds ratio 0.52) [7,16]. NICHD trial
of whole body cooling (oesophageal temperature 33.5°C for 72 h)
showed a significant reduction in the risk of death & moderate
to severe disability at 18 months in the hypothermia group [8]. TOBY
trial of whole body cooling (rectal temperature 33.5°C for 72h)
showed a significant improvement in neurologic outcome in survivors
from the hypothermic group [10]. Neo Neuro Network study [17] &
ICE trial [18] further support a beneficial effect of hypothermia.
Proposed Mechanisms of Hypothermia: Hypothermia results in a graded
reduction in cerebral metabolism by approximately 5% for each 1◦C
decrease in body temperature [3,4,7,12,19] that slows cell
depolarization, reduces accumulation of excito-toxic neurotransmitters
(aspartate, glutamate, dopamine) [20-22] & suppresses oxygen
free radical release [23] as well as lipid peroxidation of cell
membranes thereby lowering production of toxic nitric oxide
(NO) & free radicals [23]. It suppresses apoptotic processes in
the developing brain via inhibition of caspase enzymes [13,24-26].
Cytochrome C translocation is diminished by hypothermia [26, 27]
& there is increased expression of anti-apoptotic
protein BCl-2 [28]. It also suppresses the release of pro-inflammatory
cytokines & interleukins during reperfusion injury phase,
thereby reducing direct neurotoxicity via suppression of microglial
activation [29,30].The simultaneous increase in cytotoxic
oedema& loss of cerebral cortical activity that accompanies
secondary energy failure is also prevented [31].
Cooling Protocol: The target body temperature is 34.5 ◦C for selective
head cooling & 33.5 ◦C for total body cooling. Temperatures
lower than 32 ◦C are less neuroprotective & temperatures below
30 ◦C are very dangerous with severe complications [32]. Therapeutic
hypothermia must be started within the first 6 h after birth which is
the therapeutic window for hypoxic-ischemic event. Active cooling
should be done for 72 hours from the initiation of cooling with very
strict control of newborn’s body temperature. Then gradual
rewarming is done over 12 hours by increasing temperature by
0.5ºC every 2 hours.
Eligibility/criteria for therapeutic
hypothermia:
1) More than 35 weeks of gestation.
2) Less than 6 hours of age.
3) Presence of evidence of asphyxia - at least two of the following
four criteria:
i) Apgar less than 6 at 10 min or continued need for
resuscitation with positive pressure ventilation with / without chest
compressions at 10 min of age.
ii) Any acute perinatal event that may result in HIE (i.e. Abruption
placenta, cord prolapse, severe foetal heart rate
abnormality).
iii) Cord pH less than 7.0 or base deficit of 12 or
more.
iv) If cord pH is unavailable, arterial pH less than
7.0/ BE more than12 mmol/L within 60
min.
4) Clinically defined moderate or severe HIE (stage 2 or 3 based on
modified Sarnat
Classification).
5) Moderate to severely abnormal background activity on
amplitude-integrated EEG (.i.e. discontinuous, burst suppression or low
voltage +/- seizure activity).
Modes of Cooling: Therapeutic hypothermia lowers the temperature of
vulnerable deep brain structures, basal ganglia to 32-34 °C.
Brain hypothermia can be achieved by cooling the body, cooling the head
selectively, or by cooling the head & body together. Whole body
cooling provides homogeneous cooling to all brain structures, including
the peripheral & central brain regions, whereas selective head
cooling provides greater cooling to the periphery of the brain than to
the deeper brain structures [33]. The combination of head& body
cooling minimises the temperature gradients across the brain &
also facilitates the cooling of the deeper regions. To provide adequate
neuroprotection with minimal risk of systemic adverse effects, ideally
the brain only should be cooled. However, in view of a temperature
gradient between the cerebral cortex & deep grey nuclei, i.e.
structures that are often affected in acute asphyxia, mild systemic
hypothermia (34.5°C) is preferred to limit the steepness of the
intra-cerebral gradient.
Devices for Cooling: Various devices have been used for therapeutic
hypothermia.
1) Selective head cooling by circulating water at 10°C through
a coil of tubing wrapped around the head (CoolCap). A servo-controlled
overhead heater was used to maintain rectal temperature at 34°C
to 35°C
[16].
2) Placing a cap formed from cooled packs around the head at a
temperature of 10°C, to maintain a nasopharyngeal temperature
of 34°C to 35°C [34].
3) Placing infant on a water blanket pre-cooled to 5°C
&the blanket temperature was servo-controlled to maintain an
oesophageal temperature of 33.5°C [8].
4) Blowing cool air through a translucent perforated paper blanket
placed over the infant to achieve the target rectal temperature between
33.0°C to 34.0°C [16]. Nowadays hypothermia is
maintained with servo controlled systems aimed at reducing fluctuations
in body temperature.
Adverse Effects of
Cooling: There were no reported serious adverse effects
in initial four pilot studies of hypothermia in newborns [35-38]. The
potential side effects reported later include Delayed intracardiac
conduction with sinus bradycardia [39,40],
Prolonged QT interval, Ventricular arrhythmias, Reduced
cardiac output, Hypotension, Hypertension,Reduction in surfactant
production, Increase in pulmonary vascular resistance, Increase in
oxygen consumption & oxygen requirement, Altered coagulation
cascade& viscosity leading to coagulopathy that may be
complicated by thrombus or haemorrhage, Anaemia, Thrombocytopaenia,
Leukopaenia with increased risk of sepsis, Renal impairment,
Metabolic & lactic acidosis, Hypokalaemia, Hypoglycaemia,
Impaired liver function, Increase in vascular resistance, Platelet
dysfunction, Excessive fibrinolytic activity, Diuresis due to
suppression of antidiuretic hormones, Pulmonary hypertension, Impaired
leukocyte mobility &phagocytosis [16]. Adverse effects, such as
sinus bradycardia, increased blood pressure and increased oxygen
requirement, were all transient and reversible with re-warming [36].
Cooling in the presence of infection might be deleterious as
hypothermia may impair innate immune function, including neutrophil
migration and function [41]. When lowering the body
temperature, blood becomesmore viscous &the solubility of the
gases in theblood increases; for example, in vivo values
at33.5°C of PaCO2 are approximately 0.83 the valueread at
37°C. Correcting for temperature may resultin an increase in
PaCO2 with a resultant increasein cerebral blood flow, whereas
notcorrecting may result in the opposite effect, i.e.hypocapniainduced
vasoconstriction. During hypothermia, there may be an increasedrisk of
endotracheal tube obstruction due to stickysecretions which can be
avoided by setting the temperatureof the humidifier at 37°C.
During re-warming, seizures, hypotension [42], hypoglycaemia or
hypokalemia can occur.
Conclusion
Therapeutic hypothermia is a proven therapy in perinatal asphyxia
provided prompt selection of babies & religious monitoring of
temperature is done. Strict surveillance for the development of adverse
effects is mandatory. With the development of newer modes of
servo controlled hypothermia devices the cerebral insult due
to asphyxia can be reduced & severe sequlae of HIE can be
prevented.
Funding:
Nil, Conflict of
interest: Nil
Permission from IRB:
Yes
References
1. Costello AM, Manandhar DS. Perinatal asphyxia in less developed
countries. Arch Dis Child Fetal Neonatal Ed. 1994 Jul;71(1):F1-3.
[PubMed]
2. Snowden JM, Cheng YW, Kontgis CP, Caughey AB. The association
between hospital obstetric volume and perinatal outcomes in California.
Am J Obstet Gynecol. 2012 Dec;207(6):478.e1-7. doi:
10.1016/j.ajog.2012.09.029. Epub 2012 Oct 1.
3. Vannucci RC. Current and potentially new
management strategies for perinatal hypoxic-ischemic encephalopathy.
Pediatrics. 1990 Jun;85(6):961-8. [PubMed]
4. Robertson CM, Perlman M. Follow-up of the
term infant after hypoxic-ischemic encephalopathy. Paediatr Child
Health. 2006 May;11(5):278-82. [PubMed]
5. Lawn JE, Kinney M, Lee AC, Chopra M, Donnay
F, Paul VK, Bhutta ZA, Bateman M, Darmstadt GL. Reducing
intrapartum-related deaths and disability: can the health system
deliver? Int J Gynaecol Obstet. 2009 Oct;107 Suppl 1:S123-40, S140-2.
doi: 10.1016/j.ijgo.2009.07.021.
6. Lawn JE, Cousens S, Zupan J; Lancet Neonatal
Survival Steering Team. 4 million neonatal deaths: when? Where? Why?
Lancet. 2005 Mar 5-11;365(9462):891-900. [PubMed]
7. Gluckman PD, Wyatt JS, Azzopardi D, Ballard
R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M,
Whitelaw A, Gunn AJ. Selective head cooling with
mild systemic hypothermia after neonatal
encephalopathy: multicentre randomised trial.
Lancet. 2005 Feb 19-25;365(9460):663-70.
8. Shankaran SLA, Ehrenkranz RA, Tyson JE,
McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD,
Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ,
Lemons JA, Guillet R, Jobe AH, National Institute of Child Health and
Human Development Neonatal Research Network: Whole-body hypothermia for
neonates with hypoxic ischemic encephalopathy. N Engl J Med. 2005 Oct
13;353(15):1574-84.
9. Eicher DJ, Wagner CL, Katikaneni LP, Hulsey
TC, Bass WT, Kaufman DA, Horgan MJ, Languani S, Bhatia JJ, Givelichian
LM, Sankaran K, Yager JY. Moderate hypothermia in neonatal
encephalopathy: efficacy outcomes. Pediatr Neurol. 2005 Jan;32(1):11-7.
10. Azzopardi D, Strohm B, Edwards A, Dyet L,
Halliday H, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E,
Thoresen M, Whitelaw A, Brocklehurst P, Group TS: Moderate hypothermia
to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009 Oct
1;361(14):1349-58. doi: 10.1056/NEJMoa0900854.
11. Shah PS. Hypothermia: a systematic review
and meta-analysis of clinical trials. Semin Fetal Neonatal Med. 2010
Oct;15(5):238-46. doi: 10.1016/j.siny.2010.02.003. Epub 2010 Mar 7. [PubMed]
12. Edwards A, Brocklehurst P, Gunn A, Halliday
H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D:
Neurological outcomes at 18 months of age after moderate hypothermia
for perinatal hypoxic ischaemic encephalopathy: Synthesis and
meta-analysis of trial data. BMJ. 2010 Feb 9;340:c363. doi:
10.1136/bmj.c363.
13. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO,
Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic
encephalopathy. Cochrane Database Syst Rev. 2013 Jan 31;1:CD003311.
doi: 10.1002/14651858.CD003311.pub3.
14. Tagin MA, Woolcott CG, Vincer MJ, Whyte RK,
Stinson DA. Hypothermia for neonatal hypoxic ischemic encephalopathy:
an updated systematic review and meta-analysis. Arch Pediatr Adolesc
Med. 2012 Jun 1;166(6):558-66. doi: 10.1001/archpediatrics.2011.1772.
15. Shankaran S, Pappas A, McDonald SA, Vohr BR,
Hintz SR, Yolton K, Gustafson KE, Leach TM, Green C, Bara R, Petrie
Huitema CM, Ehrenkranz RA, Tyson JE,Das A, Hammond J, Peralta-Carcelen
M, Evans PW, Heyne RJ, Wilson-Costello DE, Vaucher YE, Bauer CR, Dusick
AM, Adams-Chapman I, Goldstein RF, Guillet R, Papile LA, Higgins RD;
Eunice Kennedy Shriver NICHD Neonatal Research Network. Childhood
outcomes after hypothermia for neonatal encephalopathy. N Engl J Med.
2012 May 31;366(22):2085-92. doi: 10.1056/NEJMoa1112066.
16. Gunn AJ, Gluckman PD, Gunn TR. Selective
head cooling in newborn infants after perinatal asphyxia: a
safety study . Pediatrics. 1998 Oct;102(4 Pt 1):885-92. [PubMed]
17. Jacobs S, Stewart M, Inder T et
al. ICE: the Australian cooling trial for hypoxic-ischemic
encephalopathy-in hospital outcomes. Proceedings of the Hot Topics in
Neonatology Conference. Washington DC, 2008.
18. Simbruner G, Mittal R, Rohlman F, Muche R.
European nEURO.network trial. Proceedings of the Hot Topics in
Neonatology Conference. Washington DC, Dec 7-9 2008.
19. Erecinska M, Thoresen M, Silver IA. Effects
of hypothermia on energy metabolism in Mammalian central nervous
system. J Cereb Blood Flow Metab. 2003 May;23(5):513-30. [PubMed]
20. Busto R, Globus MY, Dietrich WD, Martinez E,
Valdés I, Ginsberg MD. Effect of mild hypothermia on
ischemia-induced release of neurotransmitters and free fatty acids in
rat brain. Stroke. 1989 Jul;20(7):904-10. [PubMed]
21. Thoresen M, Satas S, Puka-Sundvall M,
Whitelaw A, Hallström A, Løberg EM, Ungerstedt U,
Steen PA, Hagberg H. Post-hypoxic hypothermia reduces cerebrocortical
release of NO and excitotoxins. Neuroreport. 1997 Oct 20;8(15):3359-62.
22. Nakashima K, Todd MM. Effects of hypothermia
on the rate of excitatory amino acid release after ischemic
depolarization. Stroke. 1996 May;27(5):913-8. [PubMed]
23. Globus MY, Alonso O, Dietrich WD, Busto R,
Ginsberg MD. Glutamate release and free radical production
following brain injury: effects of posttraumatic hypothermia.
J Neurochem. 1995 Oct;65(4):1704-11. [PubMed]
24. Northington FJ, Graham EM, Martin LJ.
Apoptosis in perinatal hypoxic-ischemic brain injury: how important is
it and should it be inhibited? Brain Res Brain Res Rev. 2005 Dec
15;50(2):244-57. Epub 2005 Oct 10.
25. Ohmura A, Nakajima W, Ishida A, Yasuoka N,
Kawamura M,Miura S, et al. Prolonged hypothermia protects neonatal
ratbrain against hypoxic-ischemia by reducing both apoptosis and
necrosis. Brain Dev. 2005;27:517---26.
26. Edwards AD, Yue X, Squier MV, Thoresen M,
Cady EB, Penrice J, Cooper CE, Wyatt JS, Reynolds EO, Mehmet H.
Specific inhibition of apoptosis after cerebral hypoxia-ischaemia by
moderate post-insult hypothermia. Biochem Biophys Res Commun. 1995 Dec
26;217(3):1193-9.
27. Xu L, Yenari MA, Steinberg GK, Giffard RG.
Mild hypothermia reduces apoptosis of mouse neurons in vitro early in
the cascade. J Cereb Blood Flow Metab. 2002 Jan;22(1):21-8.
28. Zhang, Z; Sobel, RA; Cheng, D; Steinberg,
GK; Yenari, MA. (2001). "Mild hypothermia increases Bcl-2 protein
expression following global cerebral ischemia. Brain Res Mol Brain Res.
2001 Nov 1;95(1-2):75-85. doi:10.1016/S0169-328X(01)00247-9.
29. Cornette L. Therapeutic hypothermia in
neonatal asphyxia. Facts Views Vis Obgyn. 2012;4(2):133-9. [PubMed]
30. Wassink G, Gunn ER1, Drury PP, Bennet L,
Gunn AJ. The mechanisms and treatment of asphyxial encephalopathy.
Front Neurosci. 2014 Feb 27;8:40. doi: 10.3389/fnins.2014.00040.
eCollection 2014. [PubMed]
31. Gunn AJ, Gunn TR, Gunning MI, Williams CE,
Gluckman PD. Neuroprotection with prolonged head cooling started before
postischemic seizures in fetal sheep. Pediatrics. 1998
Nov;102(5):1098-106.
32. Silveira RC, Procianoy RS. Hypothermia
therapy for newborns with hypoxic ischemic encephalopathy. J Pediatr
(Rio J). 2015 Nov-Dec;91(6 Suppl 1):S78-83. doi:
10.1016/j.jped.2015.07.004. Epub 2015 Sep 4. [PubMed]
33. Laptook AR, Shalak L, Corbett RJ.
Differences in brain temperature and cerebral blood flow during
selective head versus whole-body cooling. Pediatrics. 2001
Nov;108(5):1103-10. [PubMed]
34. Simbruner G, Haberl C, Harrison V, Linley L,
Willeitner AE. Induced brain hypothermia in asphyxiated human newborn
infants: a retrospective chart analysis of physiological and adverse
effects. Intensive Care Med. 1999 Oct;25(10):1111-7.
35. Azzopardi D, Robertson NJ, Cowan FM,
Rutherford MA, Rampling M, Edwards AD. Pilot study of
treatment with whole body hypothermia for neonatal
encephalopathy. Pediatrics. 2000 Oct;106(4):684-94.
36. Thoresen M, Whitelaw A. Cardiovascular
changes during mild therapeutic hypothermia and
rewarming in infants with hypoxic-ischemic
encephalopathy. Pediatrics. 2000 Jul;106(1 Pt 1):92-9. [PubMed]
37. Battin MR, Dezoete JA, Gunn TR, Gluckman PD,
Gunn AJ. Neurodevelopmental outcome of infants
treated with head cooling and mild hypothermia
after perinatalasphyxia. Pediatrics. 2001 Mar;107(3):480-4. [PubMed]
38. Shankaran S, Laptook A, Wright LL,
Ehrenkranz RA, Donovan EF, Fanaroff AA, Stark AR, Tyson JE, Poole K,
Carlo WA, Lemons JA, Oh W, Stoll BJ, Papile LA,Bauer CR, Stevenson DK,
Korones SB, McDonald S. Whole-body hypothermia for neonatal
encephalopathy: animal observations as a basis for a
randomized,controlled pilot study in term infants. Pediatrics. 2002
Aug;110(2 Pt 1):377-85.
39. Fugelseth D, Satas S, Steen PA, Thoresen M.
Cardiac output, pulmonary artery pressure, and patent ductusarteriosus
during therapeutic cooling after global hypoxia-ischaemia. Arch Dis
Child Fetal Neonatal Ed. 2003 May; 88(3): F223–F228.
doi: 10.1136/fn.88.3.F223.
40. Zhou WH, Shao XM, Zhang XD, Chen C, Huang
GY. [Effects of hypothermia on cardiac function in neonates with
asphyxia]. Zhonghua Er Ke Za Zhi. 2003 Jun;41(6):460-2.
41. Biggar WD, Barker C, Bohn D, Kent G. Partial
recovery of neutrophil functions during prolonged hypothermia in pigs.
J Appl Physiol (1985). 1986 Apr;60(4):1186-9.
42. Thoresen M. Supportive care during
neuroprotective hypothermia in the term newborn: adverse effects and
their prevention. Clin Perinatol. 2008 Dec;35(4):749-63, vii. doi:
10.1016/j.clp.2008.07.018.
How to cite this article?
Rabindran, Gedam DS. Therapeutic Hypothermia in Perinatal Asphyxia: Int
J Pediatr Res 2016;3(2):124-129.doi:10.17511/ijpr.2016.2.09.